Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 197

Sort by

Sort Order Select

Journal Articles

Transcriptomically Defined Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR) Phenotype Governs Mutation-Based Disease Group Assignment

Lorenz Oelschläger, Deedra Nicolet, Krzysztof Mrózek, Daniel Schnell, Najla Alotaibi, Christopher J. Walker, Alice Mims, James S. Blachly, Bayard L Powell, Jonathan E Kolitz, Eunice S. Wang, Andrew J. Carroll, Lynn van Rosmalen, Bettina Nadorp, Nathan Salomonis, H. Leighton Grimes, Maarten Fornerod, Ann-Kathrin Eisfeld

Blood (2024) 144 (Supplement 1): 641.

https://doi.org/10.1182/blood-2024-210423

Published: 2024

Journal Articles

Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML

Blood (2024) 144 (Supplement 1): 221.

https://doi.org/10.1182/blood-2024-201595

Published: 2024

Journal Articles

Normal B Cells in MBL Are Biased Toward Antigen-Experienced B Cells, with Increased Percentages of DN1 Cells in IGHV-Mutated MBL and ABC/DN2 Cells in IGHV-Unmutated MBL Suggesting Distinct Follicular/Extrafollicular Maturation Pathways

Gonzalo Blanco, Xiao J. Yan, Anita Kar Yun Ng, Andrew Shih, Jonathan E. Kolitz, Steven L. Allen, Kanti R. Rai, Nicholas Chiorazzi

Blood (2024) 144 (Supplement 1): 1851.

https://doi.org/10.1182/blood-2024-211202

Published: 2024

Journal Articles

Delivery of Foreign Antigen Selectively to Membrane IgD on CLL and Normal B Cells Leads to Superior T-Cell Activation: A Possible Approach to Restore/Enhance T-Cell Immunity and T-Cell Help

Martina Cardillo, Matthew J Friedman, Anita Ng, Randall S. Davis, Xiao J. Yan, Ashna Shah, Michael Ryan, Peter K Gregersen, Steven L. Allen, Jonathan E Kolitz, Kanti R. Rai, Paolo Ghia, Nicholas Chiorazzi

Blood (2024) 144 (Supplement 1): 1849.

https://doi.org/10.1182/blood-2024-210710

Published: 2024

Journal Articles

BRAF -Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML

Blood (2024) 144 (Supplement 1): 2921.

https://doi.org/10.1182/blood-2024-210110

Published: 2024

Journal Articles

Wilms' Tumor 1 Functions As a Tumor Suppressor to Suppress FLT3-STAT Signaling and Epigenetic Remodeling in Acute Myeloid Leukemia (CALGB 8461, 9665 and 20202; Alliance)

Blood (2023) 142 (Supplement 1): 4126.

https://doi.org/10.1182/blood-2023-188892

Published: 2023

Journal Articles

Transcriptomic Analyses Indicate That Pre-Leukemic B Cells from People with Monoclonal B Lymphocytosis Are Surprisingly Much Less Active Than Normal B Cells from People with Monoclonal B Lymphocytosis and from Healthy Donors

Xiao J. Yan, Gonzalo Blanco, Anita Ng, Andrew Shih, Martina Cardillo, Jonathan E Kolitz, Jacqueline C. Barrientos, Steven L. Allen, Joanna M. Rhodes, Kanti R. Rai, Nicholas Chiorazzi

Blood (2023) 142 (Supplement 1): 6512.

https://doi.org/10.1182/blood-2023-191042

Published: 2023

Journal Articles

End-of-Life Outcomes in Patients with Acute Myeloid Leukemia Receiving Non-Curative Chemotherapy

Richa Thakur, Stephanie Boisclair, Phyu Thin Naing, Edward Zhou, Bradley Goldberg, Erin Jou, Jonathan E Kolitz, David W Chitty

Blood (2023) 142 (Supplement 1): 3807.

https://doi.org/10.1182/blood-2023-190266

Published: 2023

Journal Articles

Ubtf- Tandem Duplications Are Recurrent Somatic Genetic Events in Adult AML and Associate with Additional Structural Variants and a Distinct Gene Expression Profile (Alliance)

Blood (2023) 142 (Supplement 1): 4312.

https://doi.org/10.1182/blood-2023-186722

Published: 2023

Journal Articles

Survival Outcomes Associated with Molecular and Cytogenetic Alterations in AML Patients Treated with Hypomethylating Agent and Venetoclax

Stephanie Boisclair, Phyu Thin Naing, Edward Zhou, Richa Thakur, Bradley Goldberg, Erin Jou, David W Chitty, Jonathan E Kolitz

Blood (2023) 142 (Supplement 1): 2904.

https://doi.org/10.1182/blood-2023-190272

Published: 2023

Journal Articles

Personalized Residual Disease Detection in Acute Myeloid Leukemia with a Multiplexed Genomic Fingerprint Predicts Patient Outcomes

Andrea B Moffitt, Joan Alexander, Asya Stepansky, Erin Boyle, Danielle Stauder, Carlos Alberto Lopez, Vernon Wu, Nausheen Hakim, Zihua Wang, Jonathan E Kolitz, Nicholas Chiorazzi, David W Chitty, Steven L. Allen, Dan Levy, Michael Wigler

Blood (2023) 142 (Supplement 1): 1594.

https://doi.org/10.1182/blood-2023-190632

Published: 2023

Journal Articles

Characterization of Comparative Clinical Outcomes and Molecular Features of Black Patients with Acute Promyelocytic Leukemia (APL) Reveals Similar Survival and Distinct Genomic Profiles

Blood (2023) 142 (Supplement 1): 389.

https://doi.org/10.1182/blood-2023-182376

Published: 2023

Journal Articles

Outcomes and Hospital Resource Utilization Associated with Decreased Ven Exposure in Acute Myeloid Leukemia Patients: A Real-World Retrospective Review

Stephanie Boisclair, Phyu Thin Naing, Edward Zhou, Richa Thakur, Erin Jou, Bradley Goldberg, David W Chitty, Jonathan E Kolitz

Blood (2023) 142 (Supplement 1): 4268.

https://doi.org/10.1182/blood-2023-185079

Published: 2023

Journal Articles

Genomic Profiles and Associated Survival Prognosticators in Black Patients with Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 837.

https://doi.org/10.1182/blood-2023-181876

Published: 2023

Journal Articles

Differences in Molecular Alterations and Clinical Outcomes By Ethnicity for Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

Edward Zhou, Stephanie Boisclair, Phyu Thin Naing, Richa Thakur, Bradley Goldberg, Erin Jou, David W Chitty, Jonathan E Kolitz

Blood (2023) 142 (Supplement 1): 7427.

https://doi.org/10.1182/blood-2023-185014

Published: 2023

Journal Articles

BRAF -Mutated Acute Myeloid Leukemia (AML) Represents a Distinct, Prognostically Poor Subgroup Enriched in Myelodysplasia-Related (MR-)AML

Blood (2023) 142 (Supplement 1): 1575.

https://doi.org/10.1182/blood-2023-185135

Published: 2023

Journal Articles

Association between Neutropenic Index for Venetoclax Exposure (NIVE) and Survival Outcomes Among AML Patients Highlighting Racial Disparities

Phyu Thin Thin Naing, Stephanie Boisclair, Edward Zhou, Richa Thakur, Erin Jou, Bradley Goldberg, David W Chitty, Jonathan E Kolitz

Blood (2023) 142 (Supplement 1): 4219.

https://doi.org/10.1182/blood-2023-190410

Published: 2023

Journal Articles

Normal B Cells in MBL Exhibit Distinct Transcriptomes Compared to Those of Healthy Individuals, Although They Differ in Activation State Based on IGHV Mutation Status

Gonzalo Blanco, Xiao J. Yan, Anita Ng, Andrew Shih, Jonathan E Kolitz, Jacqueline C. Barrientos, Steven L. Allen, Joanna M. Rhodes, Kanti R. Rai, Nicholas Chiorazzi

Blood (2023) 142 (Supplement 1): 4632.

https://doi.org/10.1182/blood-2023-190901

Published: 2023

Journal Articles

Impact of Cytarabine Pharmacogenomics on Survival of Adolescent and Young Adults with AML and Its Clinical Relevance in Black Patients

Richard J Marrero, Deedra Nicolet, Vivek M. Shastri, Krzysztof Mrózek, Christopher J. Walker, William Blum, Bayard L Powell, Jonathan E Kolitz, Joseph O Moore, Geoffrey L Uy, Wendy Stock, Andrew J Carroll, John C. Byrd, Ann-Kathrin Eisfeld, Jatinder K. Lamba

Blood (2023) 142 (Supplement 1): 2954.

https://doi.org/10.1182/blood-2023-187361

Published: 2023

Journal Articles

The Ancestry-Related Landscape of Long Non-Coding RNAs (LncRNAs) in Acute Myeloid Leukemia (AML) and Its Impact on Patient (Pt) Survival

Blood (2023) 142 (Supplement 1): 722.

https://doi.org/10.1182/blood-2023-185030

Published: 2023

NARROW

Transcriptomically Defined Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR) Phenotype Governs Mutation-Based Disease Group Assignment

Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML

Normal B Cells in MBL Are Biased Toward Antigen-Experienced B Cells, with Increased Percentages of DN1 Cells in IGHV-Mutated MBL and ABC/DN2 Cells in IGHV-Unmutated MBL Suggesting Distinct Follicular/Extrafollicular Maturation Pathways

Delivery of Foreign Antigen Selectively to Membrane IgD on CLL and Normal B Cells Leads to Superior T-Cell Activation: A Possible Approach to Restore/Enhance T-Cell Immunity and T-Cell Help

BRAF -Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML

Wilms' Tumor 1 Functions As a Tumor Suppressor to Suppress FLT3-STAT Signaling and Epigenetic Remodeling in Acute Myeloid Leukemia (CALGB 8461, 9665 and 20202; Alliance)

Transcriptomic Analyses Indicate That Pre-Leukemic B Cells from People with Monoclonal B Lymphocytosis Are Surprisingly Much Less Active Than Normal B Cells from People with Monoclonal B Lymphocytosis and from Healthy Donors

End-of-Life Outcomes in Patients with Acute Myeloid Leukemia Receiving Non-Curative Chemotherapy

Ubtf- Tandem Duplications Are Recurrent Somatic Genetic Events in Adult AML and Associate with Additional Structural Variants and a Distinct Gene Expression Profile (Alliance)

Survival Outcomes Associated with Molecular and Cytogenetic Alterations in AML Patients Treated with Hypomethylating Agent and Venetoclax

Personalized Residual Disease Detection in Acute Myeloid Leukemia with a Multiplexed Genomic Fingerprint Predicts Patient Outcomes

Characterization of Comparative Clinical Outcomes and Molecular Features of Black Patients with Acute Promyelocytic Leukemia (APL) Reveals Similar Survival and Distinct Genomic Profiles

Outcomes and Hospital Resource Utilization Associated with Decreased Ven Exposure in Acute Myeloid Leukemia Patients: A Real-World Retrospective Review

Genomic Profiles and Associated Survival Prognosticators in Black Patients with Acute Myeloid Leukemia

Differences in Molecular Alterations and Clinical Outcomes By Ethnicity for Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

BRAF -Mutated Acute Myeloid Leukemia (AML) Represents a Distinct, Prognostically Poor Subgroup Enriched in Myelodysplasia-Related (MR-)AML

Association between Neutropenic Index for Venetoclax Exposure (NIVE) and Survival Outcomes Among AML Patients Highlighting Racial Disparities

Normal B Cells in MBL Exhibit Distinct Transcriptomes Compared to Those of Healthy Individuals, Although They Differ in Activation State Based on IGHV Mutation Status

Impact of Cytarabine Pharmacogenomics on Survival of Adolescent and Young Adults with AML and Its Clinical Relevance in Black Patients

The Ancestry-Related Landscape of Long Non-Coding RNAs (LncRNAs) in Acute Myeloid Leukemia (AML) and Its Impact on Patient (Pt) Survival

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only